Abbott wins CE Mark for Amulet 360 left atrial appendage occluder in Europe

Abbott won CE Mark for its next-generation Amulet 360 left atrial appendage occluder for non-valvular AFib patients at stroke risk.

The device is designed to seal the left atrial appendage, potentially reducing reliance on long-term blood thinners.

VERITAS trial data showed 99.8% implant success; 93.9% achieved complete closure at 45 days with zero leaks over 3 mm.